Medipee | Updates

By Thomas Prokopp

Expansion of Production Know-How and Wildcards for Companists


Dear Companists,

The technical development of our device is moving forward and we have acquired a stereo lithographic printer to improve our production quality. This was possible thanks to your investment.


New manufacturing technology

It is now possible to manufacture individual components of the device even more precisely and thereby significantly raise the quality. The stereolithographic method is used especially in medicine for prototyping during product development.

Using the "DUP" (Direct UV-Light Printing) technology, a UV-liquid resin is successively solidified on a building board (directed upwards). This is done by filtering UV light through a "cut image" on the LCD screen. This process repeats itself for each layer until the desired physical object is complete. This technology enables us to produce models with far higher precision and complexity.


Medipee - DUP Technologie


Preparations for the planned first field tests are in full swing. We intend to conduct the test with at least three different user groups, each with different symptoms. One possible example is the pH-value measurement to control the acid-base balance of nutrition-conscious people. Another example would be nitrite or leukocytes of endangered groups in neurological urology.


Companists can apply for field tests

We would like to involve Companists! To do so, we decided to offer a total of 3 wildcards for the upcoming field tests until June.

If you are interested in applying, simply send a brief email with your name, address, and preferred measuring parameter to with the subject line “Feldtest 2018.” We are looking forward to receiving many applications.


Best greetings from the sunny, yet cold, Lower Rhine,

Your Medipee team


Only registered Companists can comment. Please log in to leave a comment.


Investments in crowdfunding projects offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, these investments are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by splitting their investment amount between crowdfunding campaigns rather than investing all of it in one crowdfunding campaign. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the Companists are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the Companists – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, crowdfunding investments are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 174,200




12.28 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used.

Follow us

Contact Us
Your contact for all questions about investing on Companisto:
Sascha Jung
Investor Relations

Toll-free phone number for investors

0800 - 100 267 0 (DE)
0800 - 100 267(AT / CH)

Service hours Mo-Fr 9 a.m.- 7 p.m.

Companisto GmbH
Köpenicker Str. 154
10997 Berlin
Der E-Mail-Newsletter ist jederzeit mit einem Klick abbestellbar.
Source: Own research. Based on data from the German Private Equity and Venture Capital Association - BVK, among others.
Investor Support
Please register in order to see the complete profile of Medipee.
Already registered?    Log in